CN113943344A - 一种高活性改善记忆力衍生肽及其应用 - Google Patents
一种高活性改善记忆力衍生肽及其应用 Download PDFInfo
- Publication number
- CN113943344A CN113943344A CN202111159425.3A CN202111159425A CN113943344A CN 113943344 A CN113943344 A CN 113943344A CN 202111159425 A CN202111159425 A CN 202111159425A CN 113943344 A CN113943344 A CN 113943344A
- Authority
- CN
- China
- Prior art keywords
- memory
- improving
- peptide
- activity
- derived peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 123
- 230000000694 effects Effects 0.000 title claims abstract description 33
- 235000013305 food Nutrition 0.000 claims abstract description 21
- 238000002474 experimental method Methods 0.000 claims abstract description 16
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims abstract description 13
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims abstract description 13
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims abstract description 13
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims abstract description 13
- 229960002646 scopolamine Drugs 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 11
- 206010027175 memory impairment Diseases 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 230000003078 antioxidant effect Effects 0.000 claims description 20
- 230000029087 digestion Effects 0.000 claims description 11
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 claims description 10
- 230000002496 gastric effect Effects 0.000 claims description 10
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 4
- 230000014759 maintenance of location Effects 0.000 claims description 4
- 238000004088 simulation Methods 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 3
- 230000006870 function Effects 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 25
- 235000008331 Pinus X rigitaeda Nutrition 0.000 abstract description 22
- 235000011613 Pinus brutia Nutrition 0.000 abstract description 22
- 241000018646 Pinus brutia Species 0.000 abstract description 22
- 150000001413 amino acids Chemical class 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 7
- 238000011161 development Methods 0.000 abstract description 6
- 230000002438 mitochondrial effect Effects 0.000 abstract description 6
- 238000000746 purification Methods 0.000 abstract description 5
- 238000012216 screening Methods 0.000 abstract description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract description 4
- 102000000478 Sirtuin 3 Human genes 0.000 abstract description 4
- 238000012347 Morris Water Maze Methods 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000004128 high performance liquid chromatography Methods 0.000 abstract description 3
- 238000003032 molecular docking Methods 0.000 abstract description 3
- 229920001184 polypeptide Polymers 0.000 abstract description 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 108010041218 Sirtuin 3 Proteins 0.000 abstract 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 abstract 1
- 239000007790 solid phase Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 101800000068 Antioxidant peptide Proteins 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 102000057297 Pepsin A Human genes 0.000 description 12
- 108090000284 Pepsin A Proteins 0.000 description 12
- 229940111202 pepsin Drugs 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 229920005654 Sephadex Polymers 0.000 description 8
- 239000012507 Sephadex™ Substances 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 229960003180 glutathione Drugs 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- -1 Oxygen Radical Chemical class 0.000 description 7
- 102000004142 Trypsin Human genes 0.000 description 7
- 108090000631 Trypsin Proteins 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000007087 memory ability Effects 0.000 description 7
- 239000012588 trypsin Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 238000005227 gel permeation chromatography Methods 0.000 description 4
- 230000006993 memory improvement Effects 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091005770 SIRT3 Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 230000003956 synaptic plasticity Effects 0.000 description 2
- LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 238000011814 C57BL/6N mouse Methods 0.000 description 1
- 206010070246 Executive dysfunction Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical group NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001857 fluorescence decay curve Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000001972 liquid chromatography-electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000009225 memory damage Effects 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 102000023856 peptide binding proteins Human genes 0.000 description 1
- 108091008399 peptide binding proteins Proteins 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
一种高活性改善记忆力衍生肽及其在制备改善记忆的药物、保健品或食品中的应用,属于生物技术领域。本发明对松仁高活性改善记忆力肽WYPGK的第三位脯氨酸进行常见氨基酸全替换,获得19条衍生肽,与线粒体去乙酰化酶sirtuin 3进行分子对接,经结合能筛选获得衍生肽WYEGK、WYKGK、WYSGK和WYFGK;利用多肽合成仪进行固相化学合成,并经反向高效液相色谱纯化及电喷雾质谱制备衍生肽,东莨菪碱诱导记忆损伤模型小鼠Morris水迷宫实验证明衍生肽具有高改善记忆活性。该类高活性改善记忆力肽属于天然衍生肽,安全性高,可应用于制备改善记忆力,延缓老年痴呆症发生发展的药物、保健品或食品,具有良好应用前景。
Description
技术领域
本发明属于生物技术领域,具体涉及一种高活性改善记忆力衍生肽及其在制备改善记忆的药物、保健品或食品中的应用。
背景技术
氧化应激(Oxidative Stress)是由机体内过量自由基堆积引起的氧化系统失衡,近年来随着我国老龄化人口数量递增、中青年人生活节奏加快以及各种精神压力的增大,加剧了氧化应激的发生和发展。线粒体是细胞进行氧化还原反应和能量代谢的主要场所,亦是产生活性氧(Reactive Oxygen Species,ROS)和受ROS攻击的首要靶标。损伤后的线粒体会释放大量ROS,减弱神经细胞线粒体自噬,诱发神经炎症和细胞凋亡,引起突触可塑性功能障碍,降低突触数量和密度,破坏血脑屏障完整性,造成血脑屏障渗漏,进而导致学习记忆能力减退。并且随着年龄增长,记忆功能加速恶化,一般从初期记忆障碍逐渐到失语、失认、失用、视空间损害、执行功能障碍、人格障碍等全面性功能障碍,更严重者为痴呆症。因此,靶向干预线粒体稳态,维持机体氧化防御平衡,可作为神经保护和改善学习记忆减退的有效策略。近年来,食源蛋白质和食品加工副产物因其在生物活性肽制备中的潜力而受到广泛关注,尤其是基于高抗氧化活性的改善记忆力肽。
抗氧化肽(Antioxidant peptides)是一类天然生物活性肽,通常由3-15个氨基酸组成,具有较强抗氧化活性,且活性受氨基酸组成、数量、序列和结构的影响。抗氧化肽分子量较小、容易穿过细胞膜被人体吸收利用,且安全性高,在吸收速率和生物学功能上具有显著优势。现代营养学研究发现:人类摄食的蛋白质经消化道酶作用后,大多是以低分子量肽形式消化吸收的,比游离氨基酸生物效价和营养价值更高。本发明研究表明松仁源抗氧化肽WYPGK可激活SIRT3改善东莨菪碱诱导记忆障碍小鼠突触可塑性,改善小鼠学习和记忆能力。此外,高活性改善记忆力肽可以用作食品药品配方成分,预防氧化应激相关疾病并改善学习记忆能力,还可作为食品中的添加剂抑制食品的氧化,在食品和医疗保健品领域发挥重要作用。
生物活性肽的初级结构或空间构象是决定其功能活性的关键。目前,通过酶解底物蛋白制备活性肽,其功能活性受原料蛋白一级结构限制。衍生肽开发是解决制约活性肽发展与应用问题行之有效的策略之一,也是近年来食品科学和药学领域研究中的一个重要发展方向。对高活性改善记忆力肽进行改造可赋予肽分子优良性质,同时可改变氨基酸之间空间位阻,抑制蛋白酶对肽键的水解,从而进一步提高活性肽在体内的活性和稳定性。因此,本发明在松仁蛋白经酶解、分离纯化和结构鉴定,获得了显著改善东莨菪碱模型小鼠学习记忆能力且结构明确的肽WYPGK基础上,对活性肽氨基酸组成进行改造,并结合抗氧化相关线粒体去乙酰化酶SIRT3优化筛选,最终获得高活性改善记忆力衍生肽,实现高活性改善记忆力衍生肽在食品和医疗保健品中的应用。
发明内容
本发明的目的在于提供一种高活性改善记忆力衍生肽及其在制备改善记忆的药物、保健品或食品中的应用,属于天然衍生肽,安全性高,具有高改善记忆力活性和抗氧化活性,抗酸碱稳定性和胃肠消化稳定性。
本发明所述的一种高活性改善记忆力衍生肽,其特征性在于:其氨基酸序列分别为Trp-Tyr-Glu-Gly-Lys(WYEGK)、Trp-Tyr-Lys-Gly-Lys(WYKGK)、Trp-Tyr-Ser-Gly-Lys(WYSGK)或Trp-Tyr-Phe-Gly-Lys(WYFGK)。
本发明所述的上高活性改善记忆力衍生肽,通过东莨菪碱诱导记忆损伤模型小鼠水迷宫试验,与模型组相比,衍生肽处理组小鼠逃避潜伏期由70.74s分别显著降低至35.78~40.53s,目标区域停留时间由24.24%增加至32.19~36.22%,经过平台次数由1.1次增加至3.1~3.8次。
本发明所述的上高活性改善记忆力衍生肽,通过ABTS清除率和ORAC实验测定衍生肽的抗氧化能力,在衍生肽浓度为100μM时,WYEGK、WYKGK、WYSGK和WYFGK的ABTS清除率分别达到54.48%、40.31%、70.47%和36.56%,均高于GSH的31.39%;ORAC值分别达到5422.29、3681.50、5473.16和3762.05μmol TE/g,均显著高于GSH的995.58μmol TE/g,表明本发明所述的高活性改善记忆力衍生肽具有高抗氧化活性。
本发明所述的上高活性改善记忆力衍生肽,通过酸碱稳定性和模拟胃肠道消化实验分析其稳定性。实验结果表明。酸碱(pH值2~8)条件下衍生肽几乎未发生降解,模拟胃肠消化肽含量保留率达93.45%以上。
本发明所述的上高活性改善记忆力衍生肽在制备改善记忆的药物、保健品或食品中可以得到应用,所述的药物或保健品还可以含有其他具有改善记忆力和抗氧化活性成分和/或可接受的辅料。
本发明相比现有技术的有益效果为:
本发明以松仁源高活性改善记忆力肽WYPGK为模板,保证原有N端及C端氨基酸高活性的基础上,利用19种常见氨基酸对松仁改善记忆力肽WYPGK的第三位脯氨酸进行替换,与线粒体去乙酰化酶sirtuin 3(SIRT3)进行分子对接并筛选,从而获得改善记忆活性和抗氧化活性更好、抗酸碱稳定性和胃肠消化稳定性更高的衍生肽WYEGK、WYKGK、WYSGK和WYFGK。该类衍生肽属于天然衍生肽,安全性高,具有高改善记忆力活性,抗酸碱稳定性和胃肠消化稳定性。该类衍生肽可应用于制备改善记忆力和抗氧化药物和保健品,具有良好应用前景。
本发明公布的衍生肽序列和设计方法不需要经过酶解及分离纯化便可获得高活性改善记忆力肽,设计方法简单合理。生物活性肽的初级结构或空间构象是决定其功能活性的关键。本发明采取的合理性设计和分子对接模拟筛选有利于定向获得改善记忆活性肽,具有更高活性,更高稳定性,高安全性的特点,可用于预防或延缓记忆损伤,进而延缓痴呆症的发生和发展,对药物、保健品和食品开发具有巨大潜力,必然发挥重要作用。
附图说明
图1为松仁抗氧化肽WYPGK分离纯化及结构鉴定图;(a)为超滤组分ORAC测定图谱;(b)为Sephdex G-25层析图谱;(c)为Sephdex G-25组分ORAC测定图谱;(d)为Sephdex G-15层析图谱;(e)为Sephdex G-15组分ORAC测定图谱;(f)为反向高效液相色谱分离图谱;(g)为松仁抗氧化肽WYPGK质谱图;
图2为松仁改善记忆力衍生肽WYPGK和WYSGK的小鼠Morris水迷宫试验曲线;(a)逃避潜伏期曲线;(b)目标区域停留时间柱形图;(c)经过平台次数柱形图;其中Control组为空白对照组、Model组为模型组、Piracetam组wei阳性组;
图3为松仁抗氧化肽WYPGK和松仁改善记忆力衍生肽WYEGK、WYKGK、WYSGK、WYFGK的ABTS和ORAC测定曲线;
图4为松仁改善记忆力衍生肽WYSGK的(a)温度稳定性图和(b)酸碱稳定性图;
图5为松仁改善记忆力衍生肽WYSGK的模拟胃肠道消化稳定性图,其中Control为未经肠胃消化的空白组,Pepsin 1h为胃蛋白酶消化1h,Pepsin 2h为胃蛋白酶消化2h,Pepsin 2h+Trypsin 1h为经胃蛋白酶消化2h后用胰蛋白酶消化1h,Pepsin 2h+Trypsin 2h为经胃蛋白酶消化2h后用胰蛋白酶消化2h。
具体实施方式
以下结合实施例来进一步解释本发明,但实施例并不对本发明作任何限定。
实施例1:松仁抗氧化肽WYPGK的分离纯化及结构鉴定
(1)松仁抗氧化肽酶解液的制备
以松仁清蛋白为原料,加入蒸馏水配制底物质量浓度2%的溶液,90℃水浴10min,破坏蛋白结构。冷却至室温后,用0.5mol/L NaOH调节pH至9.5,酶解温度57℃,Alcalase2.4L碱性蛋白酶添加量为8600U/g,酶解时间150min,酶解完成后经90℃灭酶10min,冷却至室温,再用0.5mol/L HCl调节pH至7.0,5000r/min离心10min取上清液,获得松仁抗氧化肽酶解液,4℃保存。
(2)超滤
将步骤(1)获得的松仁抗氧化肽酶解液进行超滤分离,选用切向流超滤系统及Biomax改良聚醚砜复合膜包,膜包截流分子质量分别为10kDa和3kDa,控制恒流泵进口压力为1.5bar,回流压力为0.4bar,获得3个组分(分子量<3kDa,3-10kDa和>10kDa),将3个组分分别收集后冷冻干燥成粉,并通过氧自由基吸附能力(ORAC)实验测定其抗氧化活性(具体实验方法见实施例3),结果表明松仁抗氧化肽分子量<3kDa组分具有更好的抗氧化活性(见附图1a)。
(3)Sephadex G-25凝胶层析
将步骤(2)得到的松仁抗氧化肽分子量<3kDa组分,加入蒸馏水配成100mg/mL的溶液,并过0.22μm的滤膜。滤液通过Sephadex G-25葡聚糖凝胶柱(1.6cm×80cm)进行分离,上样量15mL,洗脱液为蒸馏水,洗脱流速为1.5mL/min,用紫外检测仪在280nm波长下检测样品分离过程吸光度,并用自动部分收集器进行收集组分(5min/管),根据层析图谱(见附图1b,纵坐标A为吸光度值)分析获得4个组分(B1、B2、B3和B4,所获得的四个组分分子量不同,分子量由大到小),分别收集4个组分冷冻干燥成粉,并通过ORAC实验测定其抗氧化活性,结果表明松仁抗氧化肽B4组分具有更好的抗氧化活性(见附图1c)。
(4)Sephadex G-15凝胶层析
将Sephadex G-25凝胶层析分离得到的松仁抗氧化肽B4组分,加入蒸馏水配成80mg/mL的溶液,并过0.22μm的滤膜。滤液用Sephadex G-15葡聚糖凝胶柱(1.6cm×80cm)进行分离,上样量1.5mL,洗脱液为蒸馏水,洗脱流速0.8mL/min,用紫外检测仪在280nm波长下检测样品分离过程吸光度,并用自动部分收集器进行收集组分(5min/管)。根据层析图谱(见附图1d)分析获得2个组分(C1和C2,所获得的两个组分分子量不同,分子量由大到小),分别收集2个组分冷冻干燥成粉,并通过ORAC实验测定其抗氧化活性,结果表明松仁抗氧化肽C2组分具有更好的抗氧化活性(见附图1e)。
(5)反向高效液相色谱
将Sephadex G-15凝胶层析分离得到的松仁抗氧化肽C2组分,加入蒸馏水配成样品浓度为40mg/mL的溶液,并过0.22μm的滤膜,并取滤液上RP-HPLC系统进行分离纯化,色谱条件为:C18(4.6×150mm),检测波长220nm,上样量50μL,流速0.5mL/min,柱温:25℃;A相:水+体积分数为0.1%的三氟乙酸;B相:甲醇+体积分数为0.1%的三氟乙酸,液相洗脱条件见表1。将分离得到的组分收集冷冻干燥成粉,将收集组分送样做质谱鉴定(见附图1f和1g,图1f曲线为液相分离图谱,纵坐标AU为吸光度,吸光度高则该组分肽含量和纯度高,收集D6-D9四个组分,所获得的四个组分肽极性不同,极性由大到小)。
表1:流动相洗脱条件表
时间(min) | A(%) | B(%) |
0 | 95 | 5 |
30 | 70 | 30 |
50 | 70 | 30 |
60 | 95 | 5 |
(6)多肽结构鉴定
多肽结构鉴定使用美国Thermo赛默飞世尔科技有限公司QE质谱仪进行LC-ESI-MS/MS质谱测定。采用电喷雾正离子扫描模式(ESI+);质量扫描范围m/z 50~750;鞘气(N2),压力为40au;辅助气(N2)5au;喷雾压力为4.5KV;传输毛细管温度350℃;二级质谱碰撞电压15eV。收集谱图数据,用PEAKS软件进行De Novo Sequencing氨基酸序列分析。通过数据库和文献查阅,将质谱鉴定获得肽段进行筛选得到松仁抗氧化肽WYPGK(见附图1g)。
实施例2:高活性改善记忆力衍生肽改善东莨菪碱诱导记忆损伤模型小鼠学习记忆能力
分别用19种常见氨基酸(甘氨酸G、丙氨酸A、缬氨酸V、亮氨酸L、异亮氨酸I、甲硫氨酸M、色氨酸W、丝氨酸S、酪氨酸K、半胱氨酸C、苯丙氨酸F、天冬酰胺N、谷氨酰胺Q、苏氨酸T、天冬氨酸D、谷氨酸E、赖氨酸L、精氨酸R和组氨酸H)替换(所述的19条衍生肽可以按这个序列由生物公司直接合成得到)松仁抗氧化肽WYPGK第三位脯氨酸(P),获得19条衍生肽序列(WYGGK、WYAGK、WYVGK、WYLGK、WYIGK、WYMGK、WYWGK、WYSGK、WYKGK、WYCGK、WYFGK、WYNGK、WYQGK、WYTGK、WYDGK、WYEGK、WYLGK、WYRGK和WYHGK),将19条衍生肽与线粒体去乙酰化酶sirtuin 3(SIRT3)进行分子对接,并利用结合能进行筛选,确定衍生肽WYSGK结合能为-5.87,衍生肽WYEGK结合能为-1.44,衍生肽WYKGK结合能为-1.94,衍生肽WYFGK结合能为-6.08,WYEGK、WYKGK、WYSGK、WYFGK、WYPGK分别进行固相合成(参照Sheppard R.方法,J.Pept.Sci.2003;9:545.)获得5条肽的固体,并通过东莨菪碱诱导记忆损伤模型小鼠改善记忆力活性分析。
小鼠研究按照欧盟委员会出版的《实验动物护理和使用指南》进行。雄性C57BL/6N小鼠购自辽宁长盛生物科技有限公司(中国本溪),体重25-30g。小鼠饲养温度稳定(22±1℃),12小时/12小时光/暗循环。小鼠随意喂食标准食物和水。小鼠被分为五组(n=10/组):(i)用盐水作为载体灌胃小鼠36天(空白对照);(ii)用盐水灌胃30天和东莨菪碱(1mg/kg)灌胃6天的小鼠(模型);(iii)用盐水灌胃30天并用拉西坦(60mg/kg)和东莨菪碱(1mg/kg)灌胃6天的小鼠(阳性);(iv)用分数<3kDa(600mg/kg)灌胃30天和分数<3kDa(600mg/kg)和东莨菪碱(1mg/kg)灌胃6天(<3kDa)的小鼠;(v)用肽WYPGK(60mg/kg)灌胃30天和用肽WYPGK(60mg/kg)和东莨菪碱(1mg/kg)灌胃6天(WYPGK)的小鼠。
Morris水迷宫行为学实验
(1)定位航向实验
向直径为1200mm的水迷宫圆池内注入20±2℃的温水,同时将平台(直径65mm)放在距离水面1cm的SW象限中。将小鼠面向池壁轻轻放入NE象限,图像采集系统记录小鼠游泳轨迹,同时并计时120s。小鼠在120s内找到SW象限内平台所用的时间记为潜伏期,到达平台的小鼠在台上停留10s后放回笼中。未能在120s内找到平台的小鼠被引导至平台,同时也让其在台上停留10s,潜伏期记为120s。随后,根据数据采集系统,分析并计算小鼠从放入水中到找到平台的时间(见附图2a)。如图2a所示,在5天的训练中,与空白组(Control)相比,模型组(Model)小鼠逃避潜伏期长,说明模型组小鼠记忆损伤,与模型组相比,衍生肽WYPGK和WYSGK组小鼠逃避潜伏期变短,潜伏期短说明小鼠记忆力好,因此衍生肽WYPGK和WYSGK组小鼠记忆损伤缓解,衍生肽WYPGK和WYSGK具有改善东莨菪碱诱导记忆损伤模型小鼠学习记忆能力的作用。
(2)空间探索实验
定位航向实验结束后,将放在水下的平台取出。将小鼠面向池壁轻轻放入NE象限,图像采集系统记录小鼠游泳轨迹,同时并计时90s。根据数据采集系统,分析并计算小鼠90s内有效区域停留时间(见附图2b),穿越原平台次数(见附图2c)。如图2b和2c所示,与空白组(Control)相比,模型组(Model)小鼠有效区域停留时间和穿越原平台次数明显减少,说明模型组小鼠记忆损伤,与模型组相比,衍生肽WYPGK和WYSGK组小鼠有效区域停留时间和穿越原平台次数显著增加,说明衍生肽WYPGK和WYSGK组小鼠记忆损伤缓解,衍生肽WYPGK和WYSGK具有改善东莨菪碱诱导记忆损伤模型小鼠学习记忆能力的作用。
实施例3:松仁抗氧化肽的衍生肽抗氧化活性测定(见附图3)
(1)ABTS自由基清除能力测定:将7mmol/L的ABTS水溶液和2.49mmol/L的过硫酸钾水溶液等体积混合后,避光放置12h后制得ABTS自由基储备液,于4℃条件下保存。使用时,加入5mmol/L的PBS稀释,使溶液在734nm波长下吸光度为0.700±0.002,制成ABTS自由基工作液。取10μL浓度均为100μM的衍生肽水溶液,同浓度的谷胱甘肽(GSH)作为对照,分别加入到96孔板中,再加入190μL ABTS自由基工作液,准确反应6min后使用酶标仪于734nm波长下测定吸光值(A1)。清除率计算公式如下:
式中:A0为用蒸馏水代替衍生肽溶液的吸光值;
A1为加入衍生肽或谷胱甘肽的溶液吸光值;
A2为用5mmol/L的PBS溶液代替ABTS自由基工作液的溶液吸光值。
(2)氧自由基吸附能力(ORAC)测定:(1)在96孔黑板中,分别加入25μL的磷酸缓冲液、Trolox标准液(浓度12.5μM、25μM、50μM和100μM)和5条衍生肽水溶液(浓度100μM)。将96孔板放入预热30min的酶标中震荡5s,37℃温育10min。用多孔道移液枪向各孔加入150μLFL作液,震荡5s,37℃温育20min。用多孔道移液枪于各孔中迅速加入25μL的AAPH,震荡5s后进行读数。以激发波长(485±20)nm、发射波长(530±20)nm连续测定荧光强度,整个体系保持37℃,每2min测定一次荧光强度,每次测定前中速震动孔板10s,振荡幅度4mm,测定时间为达到初荧光强度的5%为止(本实验设置60个循环)。相对荧光强度采用近似积分法计算荧光衰退曲线下面积(AUC):
AUC=0.5×[2×(f0+f1…+fn-1+fn)-f0-fn]×△t
(1)式中,fn第n个测定点的相对荧光强度;△t为相邻时间点之间的间隔时间2min。
(2)测定结果以ORAC值表示。待测样品的ORAC值以μmol TE/g表示。
ORAC值=[(AUC样品-AUC空白)/(AUCTrolox-AUC空白)]×CTrolox/C样品。
其中AUC样品为5条衍生肽水溶液的结果;AUC空白为加25μL的磷酸缓冲液的结果;AUCTrolox为加Trolox标准液(浓度100μM)的结果;CTrolox是Trolox摩尔浓度,即100μM;
C样品衍生肽的摩尔浓度,通过Trolox标准曲线计算得出,其中Trolox标准曲线为y=0.0756x+41.989R2=0.9931,横坐标为Trolox摩尔浓度(12.5μM、25μM、50μM和100μM),纵坐标为AUCTrolox。
如图3所示,在ABTS实验中,右纵坐标为ABTS清除率,与阳性对照谷胱甘肽(GSH)相比,衍生肽WYEGK、WYKGK、WYSGK和WYFGK的ABTS清除率分别达到54.48%、40.31%、70.47%和36.56%,均高于GSH的31.39%;在ORAC实验中,左纵坐标为ORAC氧自由基吸附能力,衍生肽WYEGK、WYKGK、WYSGK和WYFGK的ORAC值分别达到5422.29、3681.50、5473.16和3762.05μmol TE/g,均显著高于GSH的995.58μmol TE/g,表明本发明所述的高活性改善记忆力衍生肽具有高抗氧化活性。
实施例4:松仁抗氧化肽的衍生肽稳定性测定
对于肽稳定性测定,具体实验操作如下:
热稳定性测定(见附图4a):
(1)将衍生肽WYSGK固体粉末,用蒸馏水溶解成100μM溶液,并将pH值调至7.0,置于4℃保存备用;
(2)将步骤(1)的衍生肽WYSGK溶液分成5管(1mL/管)分别置于20、40、60、80、100℃条件下水浴2h;
(3)将空白组(没有经过水浴处理的步骤(1)的衍生肽WYSGK溶液)和各温度下的衍生肽WYSGK溶液通过0.22μm孔径的滤膜;
(4)利用RP-HPLC分析,检测波长:220nm;柱温:25℃。流动相A:乙腈+体积分数0.1%TFA;流动相B:乙腈+体积分数0.1%TFA。洗脱条件:0-25min,10%-35%B(液相设备输入数值即可),流速1.0mL/min;
(5)根据液相图谱的峰面积大小计算衍生肽WYSGK在不同温度下是否发生降解(参照刘鑫烔方法,食品工业科技,Vol.41,No.19,2020)。
酸碱稳定性测定(见附图4b):
(1)将衍生肽WYSGK固体粉末,用蒸馏水溶解成100μM溶液,作为空白组,置于4℃保存备用;
(2)将衍生肽WYSGK固体粉末分别用pH值为2、4、6、8的水溶液稀释成100μmol/L的浓度,37℃水浴2h;
(3)将空白组和各pH值条件下的WYSGK样品溶液通过0.22μm孔径的滤膜;
(4)利用RP-HPLC分析,检测波长:220nm;柱温:25℃。流动相A:100%乙腈+0.1%TFA;流动相B:100%乙腈+0.1%TFA。洗脱条件:0-25min,10%-35%B(梯度洗脱),流速1.0mL/min;
(5)根据液相图谱的峰面积大小计算衍生肽WYSGK在不同pH值下是否发生降解(参照刘鑫烔方法,食品工业科技,Vol.41,No.19,2020)。
如图4所示,通过热稳定性和酸碱稳定性实验分析,温度在20-100℃条件下和酸碱(pH值2、4、6、8)条件下衍生肽几乎未发生降解,说明衍生肽WYSGK稳定性良好。
肽模拟胃肠道消化稳定性测定(见附图5):
(1)用pH值为2的水溶液将衍生肽WYSGK固体粉末溶解成100μM浓度的溶液;
(2)按照每1mL衍生肽溶液加入5mg胃蛋白酶(酶活为1:3000),37℃水浴1h后第一次取样1mL,模拟衍生肽胃液消化1h,置于4℃备用,37℃继续水浴,再1h后第二次取样1mL,模拟衍生肽胃液消化2h,置于4℃备用;将剩余胃蛋白酶酶解后溶液pH值调至7,按照每1mL衍生肽溶液加入5mg胰蛋白酶(酶活为1:250),37℃继续水浴,1h后第三次取样1mL,模拟衍生肽肠道消化1h,置于4℃备用;37℃继续水浴,再1h后第四次取样1mL,模拟衍生肽肠道消化2h,置于4℃备用;
2h后取出样品,37℃水浴2h,每隔1h取样,置于4℃备用;
(3)将上述(2)备用的WYSGK样品溶液分别过0.22μm孔径滤膜;
(4)利用RP-HPLC分析,检测波长:220nm;柱温:25℃。流动相A:100%乙腈+0.1%TFA;流动相B:100%乙腈+0.1%TFA。洗脱条件:0-25min,10%-35%B(梯度洗脱),流速1.0mL/min;
(5)根据液相图谱的峰面积大小计算衍生肽WYSGK在经过胃蛋白酶和胰蛋白酶酶解后是否发生降解(参照刘鑫烔方法,食品工业科技,Vol.41,No.19,2020)。
如图5所示,通过模拟胃肠道消化实验分析,在胃蛋白酶和胰蛋白酶作用下,衍生肽WYSGK肽含量保留率达93.45%以上,具有较好的胃肠消化稳定性。
Claims (6)
1.一种高活性改善记忆力衍生肽,其特征在于:其氨基酸序列分别为
Trp-Tyr-Glu-Gly-Lys(WYEGK)、Trp-Tyr-Lys-Gly-Lys(WYKGK)、Trp-Tyr-Ser-Gly-Lys(WYSGK)或Trp-Tyr-Phe-Gly-Lys(WYFGK)。
2.如权利要求1所述的一种高活性改善记忆力衍生肽,其特征在于:通过东莨菪碱诱导记忆损伤模型小鼠水迷宫试验,与模型组相比,衍生肽处理组小鼠逃避潜伏期由70.74s分别降低至35.78~40.53s,目标区域停留时间由24.24%增加至32.19~36.22%,经过平台次数由1.1次增加至3.1~3.8次。
3.如权利要求1所述的一种高活性改善记忆力衍生肽,其特征在于:通过ABTS清除率和ORAC实验测定衍生肽的抗氧化能力,在浓度为100μM时,WYEGK、WYKGK、WYSGK和WYFGK的ABTS清除率分别达到54.48%、40.31%、70.47%和36.56%,ORAC值分别达到5422.29、3681.50、5473.16和3762.05μmol TE/g,表明衍生肽具有高抗氧化活性。
4.如权利要求1所述的一种高活性改善记忆力衍生肽,其特征在于:通过酸碱稳定性和模拟胃肠道消化实验分析衍生肽稳定性,pH值2~8条件下衍生肽几乎未发生降解,模拟胃肠消化肽含量保留率达93.45%以上。
5.权利要求1~4任何一项所述的高活性改善记忆力衍生肽在制备改善记忆的药物、保健品或食品中的应用。
6.如权利要求5所述的高活性改善记忆力衍生肽在制备改善记忆的药物、保健品或食品中的应用,其特征在于:所述的药物、保健品或食品含有其他具有改善记忆力成分和/或可接受的辅料。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111159425.3A CN113943344B (zh) | 2021-09-30 | 2021-09-30 | 一种高活性改善记忆力衍生肽及其应用 |
US17/936,424 US11780880B2 (en) | 2021-09-30 | 2022-09-29 | High-activity memory-improving derivative peptide and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111159425.3A CN113943344B (zh) | 2021-09-30 | 2021-09-30 | 一种高活性改善记忆力衍生肽及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113943344A true CN113943344A (zh) | 2022-01-18 |
CN113943344B CN113943344B (zh) | 2024-03-15 |
Family
ID=79329017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111159425.3A Active CN113943344B (zh) | 2021-09-30 | 2021-09-30 | 一种高活性改善记忆力衍生肽及其应用 |
Country Status (2)
Country | Link |
---|---|
US (1) | US11780880B2 (zh) |
CN (1) | CN113943344B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2330125A2 (en) * | 2005-08-11 | 2011-06-08 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
CN103892390A (zh) * | 2014-03-22 | 2014-07-02 | 南通蛇类治疗研究所 | 富硒锗螺旋藻灵芝谷物蔬菜天然饮料 |
CN104473066A (zh) * | 2014-10-23 | 2015-04-01 | 苏州垣梦新能源环保科技有限公司 | 一种食疗(功能)营养料及其制备方法 |
WO2015101984A1 (en) * | 2014-01-02 | 2015-07-09 | Two To Biotech Ltd. | Novel polypeptides |
-
2021
- 2021-09-30 CN CN202111159425.3A patent/CN113943344B/zh active Active
-
2022
- 2022-09-29 US US17/936,424 patent/US11780880B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2330125A2 (en) * | 2005-08-11 | 2011-06-08 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
WO2015101984A1 (en) * | 2014-01-02 | 2015-07-09 | Two To Biotech Ltd. | Novel polypeptides |
CN103892390A (zh) * | 2014-03-22 | 2014-07-02 | 南通蛇类治疗研究所 | 富硒锗螺旋藻灵芝谷物蔬菜天然饮料 |
CN104473066A (zh) * | 2014-10-23 | 2015-04-01 | 苏州垣梦新能源环保科技有限公司 | 一种食疗(功能)营养料及其制备方法 |
Non-Patent Citations (4)
Title |
---|
EFFECT OF PEPTIDE SIZE ON ANTIOXIDANT PROPERTIES OF AFRICAN YAM BEAN SEED (SPHENOSTYLIS STENOCARPA) PROTEIN HYDROLYSATE FRACTIONS: ""Effect of Peptide Size on Antioxidant Properties of African Yam Bean Seed (Sphenostylis stenocarpa) Protein Hydrolysate Fractions "", 《INTERNATIONAL JOURNAL OF MOLECULAR SCIENCE》, no. 12, pages 6685 - 6702 * |
HONGYAN LU等: ""Pine nut antioxidant peptides ameliorate thememory impairment in a scopolamine-inducedmouse modelviaSIRT3-induced synapticplasticity"", 《FOOD&FUNCTION》, no. 12, pages 8026 - 803 * |
IFEANYI D. NWACHUKWU等: ""Struction and Functional properties of food protein-derived antioxidant peptides"", 《FOOD BIOCHEMISTRY》, no. 43, pages 258 - 13 * |
冷帅辰等: ""长白山松子抗氧化肽制备及活性研究"", 《食品研究与开发》, vol. 35, no. 13, pages 1 - 5 * |
Also Published As
Publication number | Publication date |
---|---|
US11780880B2 (en) | 2023-10-10 |
US20230104490A1 (en) | 2023-04-06 |
CN113943344B (zh) | 2024-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yang et al. | Preparation and characterization of gelatin and antioxidant peptides from gelatin hydrolysate of skipjack tuna (Katsuwonus pelamis) bone stimulated by in vitro gastrointestinal digestion | |
Jiang et al. | Contribution of specific amino acid and secondary structure to the antioxidant property of corn gluten proteins | |
CN107163128B (zh) | κ-酪蛋白来源生物活性肽的制备和应用 | |
Wang et al. | Isolation and identification of a novel peptide from zein with antioxidant and antihypertensive activities | |
Nadalian et al. | Isolation, purification and characterization of antioxidative bioactive elastin peptides from poultry skin | |
Shi et al. | Purification and the secondary structure of a novel angiotensin I-converting enzyme (ACE) inhibitory peptide from the alcalase hydrolysate of seahorse protein | |
CN111100186B (zh) | 一种具有ace抑制活性的河鲀多肽及其制备方法 | |
CN110606872B (zh) | 一种促皮肤创伤修复的抗氧化多肽oa-gl17及其制备方法与应用 | |
CN111004309B (zh) | 一种以菊黄东方鲀鱼皮为原料的ace抑制肽及制备方法 | |
CN111518164B (zh) | Ace抑制肽p2、其应用及其制备方法 | |
CN105131086A (zh) | 一种六肽及其应用 | |
CN111777664A (zh) | 一种核桃粕抗氧化肽yfw及其制备方法与应用 | |
CN111423495A (zh) | 具有抗氧化应激损伤的脉红螺多肽及其制备方法与应用 | |
Komisarenko et al. | Study of Amino acid composition and immunomodulatory activity of Rubus idaeus alcoholic extract | |
CN104693272A (zh) | 牦牛乳乳清蛋白具有抗氧化活性的三肽及其应用和组合物 | |
Zhang et al. | The research progress of bioactive peptides derived from traditional natural products in China | |
CN106916203B (zh) | 一种棕榈酰化七肽、及其纯化方法和应用 | |
CN112877390B (zh) | 一种功能性醇溶鲟鱼软骨制剂的制备方法 | |
CN113943344B (zh) | 一种高活性改善记忆力衍生肽及其应用 | |
CN109748951B (zh) | 一种当归抗氧化多肽及其制备方法与应用 | |
CN111777665A (zh) | 一种核桃粕抗氧化肽faw及其制备方法与应用 | |
CN113164769A (zh) | 脑功能调节剂以及含有其的食品或饮料产品 | |
CN111499691B (zh) | Ace抑制肽p1、其应用及其制备方法 | |
CN113087773B (zh) | 一种具有降血糖和抗氧化功能的牦牛骨肽及其制备方法 | |
CN105131085A (zh) | 一种五肽及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |